Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2020-01-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
第四届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company 云南沃森生物技术股份有限公司. It details the convening of the fourth board's sixth meeting, the approval of a proposal to hold the 2020 first extraordinary general meeting, and the voting results. There is no financial data, audit information, or detailed report content. The document is an announcement of board/management decisions, specifically about meeting resolutions and shareholder meeting arrangements. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or a notice of report publication, so it is not RPA or RNS. Hence, the classification is MANG with high confidence.
2020-01-22 Chinese
关于召开2020年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice for convening the 2020 first extraordinary general meeting of shareholders of Yunnan Watson Biotechnology Co., Ltd. It includes details about the meeting date, voting procedures, registration methods, and agenda items such as a proposal to change the use of raised funds. There are no financial statements or detailed financial data presented. The document is primarily an announcement and invitation to shareholders to attend and vote at the meeting, not the meeting minutes or voting results. The document length is under 5,000 characters and it serves as a notification for the meeting rather than the report or results of the meeting itself. Therefore, it fits the category of AGM Information (AGM-R) which covers presentations and materials shared during or for the Annual General Meeting or similar shareholder meetings.
2020-01-22 Chinese
关于二价HPV疫苗临床研究Ⅲ期临床试验数据揭盲进入统计分析与临床研究总结阶段的情况公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the progress of clinical trial data analysis for a vaccine. It discusses the completion of Phase III clinical trial data unblinding and the next steps in regulatory approval. The document explicitly states it is an announcement about the clinical research progress and its potential impact on company performance, not a detailed financial report or regulatory filing. The length is short (1193 characters), and it does not contain financial statements or detailed financial data. It is not a report itself but an announcement of clinical trial progress and regulatory status. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-01-17 Chinese
关于13价肺炎球菌多糖结合疫苗收到药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration approval for a vaccine product. It details the approval from the national drug regulatory authority, product information, development history, market potential, and risk factors. The document is relatively short (2267 characters) and serves as a formal notification to shareholders and the public about a regulatory milestone rather than a financial or operational report. There are no financial statements, earnings data, or management discussion of financial results. It is not a report publication announcement since it does not mention the release of a report but rather announces a regulatory approval event. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-01-10 Chinese
关于股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a disclosure about a change in shareholder equity, specifically a reduction in shareholding by a significant shareholder and their related parties. It details the shareholding percentages before and after the transaction, the nature of the transaction (a reduction in shares held), and compliance with relevant regulations. The document does not contain financial statements or detailed financial performance data, nor is it an announcement of a report publication. It is a notification of a change in major shareholding levels, which fits the definition of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, confirming this classification.
2019-12-31 Chinese
关于公司13价肺炎球菌多糖结合疫苗上市注册申请获得批准的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about the approval of a vaccine registration application by the National Medical Products Administration (国家药品监督管理局). It contains no financial data, no detailed report, and is only informing the market about a regulatory approval event. The document length is only 1073 characters, which is quite short and fits the pattern of an announcement rather than a full report. It does not contain financial statements or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2019-12-31 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.